Global IP Scale Fertin Pharma sits on a broad patent portfolio (over 500 patents) and produces billions of units annually with lean, scalable operations across Denmark, Canada, and India, enabling rapid development to commercialization of oral and intra-oral delivery products for pharma and nutraceutical brands.

End-to-End CDMO As an integrated CDMO, Fertin covers ideation and R&D through manufacturing, packaging and regulatory compliance, helping brands shorten timelines and reduce risk when launching new oral delivery formats.

Global Compliance Global regulatory know-how and a distributed footprint position Fertin to support multi-market launches, navigate complex regulatory landscapes, and ensure quality at scale for fast-moving consumer health products.

PMI Synergy PMI’s acquisition of Fertin Pharma Group highlights strong corporate backing and strategic fit for nicotine and smoke-free portfolios; this relationship may present channel opportunities for contract manufacturing support and expansion aligned with PMI’s product roadmap.

Innovative Licensing Fertin’s history of launching licensing-ready products such as caffeine chewing gum demonstrates capability to deliver novel consumer-friendly formulations and license-ready IP to consumer brands seeking fast, differentiated oral delivery solutions.